{"id":953313,"date":"2026-04-21T08:34:12","date_gmt":"2026-04-21T12:34:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-announces-closing-of-transaction-with-nexgel\/"},"modified":"2026-04-21T08:34:12","modified_gmt":"2026-04-21T12:34:12","slug":"celularity-announces-closing-of-transaction-with-nexgel","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-announces-closing-of-transaction-with-nexgel\/","title":{"rendered":"Celularity Announces Closing of Transaction with NexGel"},"content":{"rendered":"<div class=\"mw_release\">\n<p>FLORHAM PARK, N.J., April  21, 2026  (GLOBE NEWSWIRE) &#8212; Celularity Inc. (Nasdaq: CELU) (\u201cCelularity\u201d), a longevity-focused regenerative and cellular medicine company, today announced the closing of its previously announced transaction with NexGel, Inc. (\u201cNexGel\u201d), pursuant to which NexGel acquired certain commercial and other assets related to Celularity\u2019s biomaterials product portfolio and received an exclusive license to develop and commercialize specified products. The transaction is intended to monetize Celularity\u2019s biomaterials portfolio while enabling it to further concentrate resources on advancing its longevity-focused therapeutic pipeline and scalable manufacturing platform.<\/p>\n<p>Under the terms of the transaction, Celularity received aggregate consideration of $13.3 million, consisting of $8.3 million in cash at closing and a $5.0 million convertible promissory note from NexGel. In addition, Celularity remains eligible to receive up to $20.0 million in future milestone payments based on net sales thresholds, and royalties on net sales of certain development-stage products, in each case subject to the terms of the transaction documents. The transaction also enabled Celularity to retire nearly $13.0 million of debt, strengthening Celularity\u2019s balance sheet and capital position while preserving future economic participation in certain licensed development-stage programs.<\/p>\n<p>\u201cThis transaction with NexGel marks an important step in Celularity\u2019s ongoing efforts to sharpen strategic focus, monetize non-core biomaterials assets and strengthen Celularity\u2019s capital position as we advance our longevity-focused strategy,\u201d said Robert J. Hariri, M.D., Ph.D., Celularity\u2019s Founder, Chairman and Chief Executive Officer. \u201cBy streamlining our biomaterials activities while retaining the opportunity to participate in future milestone and royalty economics, we are further aligning resources around high-value cellular therapeutics and other programs targeting the fundamental mechanisms of aging.\u201d<\/p>\n<p>\n        <strong>About Celularity<\/strong>\n      <\/p>\n<p>Celularity Inc. (Nasdaq: CELU) is a longevity-focused regenerative and cellular medicine company developing and manufacturing allogeneic and autologous cell therapies derived from the postpartum placenta. Celularity leverages the placenta\u2019s unique biology, immunologic properties, and scalable availability to develop therapeutic solutions targeting fundamental mechanisms of aging and age-related disease.<\/p>\n<p>For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=msbKb0cYFJufpT9cZaZ1T_6f-O022Ne0F-xa1BUbZNk7PsOeOIzAxGUeV2F9jJ3e8U6tlhb8mt-G-od8vO8V9ntgssgFqaqLspqOOnYKvJKjFMTI3Y_m808HG6OwlQEV2h1pGtYe9YwHk4FD_XFz5C8wTYcPHwuZt-qqw5MG_hIiC9ZYK05qY8W4lh-SthZEIsg_Ux7fA3t2Y76prtg1s8ZppT0BGwWdzCVQFZ1f6f47hTbwns8ZV08a2jeE_uq8FpBVRnNjhuxIWr41yIuK8g==\" rel=\"nofollow\" target=\"_blank\">www.celularity.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the expected benefits of the transaction with NexGel, Celularity\u2019s ability to receive future royalty and milestone payments, the anticipated balance sheet and capital position benefits of the transaction, and Celularity\u2019s strategic plans, including its longevity-focused strategy, and Celularity\u2019s ability to realize the anticipated strategic and financial benefits of the transaction. These forward-looking statements are based on current beliefs, expectations and assumptions and are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to NexGel\u2019s commercialization of the licensed products, the achievement of royalty and milestone thresholds, and other risks and uncertainties described in Celularity\u2019s filings with the Securities and Exchange Commission. Celularity undertakes no obligation to update any forward-looking statements except as required by law.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><\/p>\n<p>Carlos Ramirez<br \/>Senior Vice President, Celularity Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=e2V6650ao2lP4p6t-gdXEQAkpoMwuhkp-uPpqyePYs1RUzOSs5qJ6KKtA5xeHyuQKRxdisWpXF0hRWVeZT3nvEu1Nl21sPsOGUkyb6KZFu9Hh5vM2nceIDV6gt7xo0YI\" rel=\"nofollow\" target=\"_blank\"><u>Carlos.ramirez@celularity.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MzczMSM3NTQ2NjcyIzIyMDUwMDk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDdlZDY3ZmYtNGQwNi00M2U2LWFiZGQtYjdkODg0YjNiMzFhLTEyMTY1NjItMjAyNi0wNC0yMS1lbg==\/tiny\/Celularity-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) &#8212; Celularity Inc. (Nasdaq: CELU) (\u201cCelularity\u201d), a longevity-focused regenerative and cellular medicine company, today announced the closing of its previously announced transaction with NexGel, Inc. (\u201cNexGel\u201d), pursuant to which NexGel acquired certain commercial and other assets related to Celularity\u2019s biomaterials product portfolio and received an exclusive license to develop and commercialize specified products. The transaction is intended to monetize Celularity\u2019s biomaterials portfolio while enabling it to further concentrate resources on advancing its longevity-focused therapeutic pipeline and scalable manufacturing platform. Under the terms of the transaction, Celularity received aggregate consideration of $13.3 million, consisting of $8.3 million in cash at closing and a $5.0 million convertible promissory note from NexGel. In addition, Celularity &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-announces-closing-of-transaction-with-nexgel\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Celularity Announces Closing of Transaction with NexGel&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-953313","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Celularity Announces Closing of Transaction with NexGel - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-announces-closing-of-transaction-with-nexgel\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celularity Announces Closing of Transaction with NexGel - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) &#8212; Celularity Inc. (Nasdaq: CELU) (\u201cCelularity\u201d), a longevity-focused regenerative and cellular medicine company, today announced the closing of its previously announced transaction with NexGel, Inc. (\u201cNexGel\u201d), pursuant to which NexGel acquired certain commercial and other assets related to Celularity\u2019s biomaterials product portfolio and received an exclusive license to develop and commercialize specified products. The transaction is intended to monetize Celularity\u2019s biomaterials portfolio while enabling it to further concentrate resources on advancing its longevity-focused therapeutic pipeline and scalable manufacturing platform. Under the terms of the transaction, Celularity received aggregate consideration of $13.3 million, consisting of $8.3 million in cash at closing and a $5.0 million convertible promissory note from NexGel. In addition, Celularity &hellip; Continue reading &quot;Celularity Announces Closing of Transaction with NexGel&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-announces-closing-of-transaction-with-nexgel\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-21T12:34:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MzczMSM3NTQ2NjcyIzIyMDUwMDk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-announces-closing-of-transaction-with-nexgel\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-announces-closing-of-transaction-with-nexgel\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Celularity Announces Closing of Transaction with NexGel\",\"datePublished\":\"2026-04-21T12:34:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-announces-closing-of-transaction-with-nexgel\\\/\"},\"wordCount\":511,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-announces-closing-of-transaction-with-nexgel\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MzczMSM3NTQ2NjcyIzIyMDUwMDk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-announces-closing-of-transaction-with-nexgel\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-announces-closing-of-transaction-with-nexgel\\\/\",\"name\":\"Celularity Announces Closing of Transaction with NexGel - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-announces-closing-of-transaction-with-nexgel\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-announces-closing-of-transaction-with-nexgel\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MzczMSM3NTQ2NjcyIzIyMDUwMDk=\",\"datePublished\":\"2026-04-21T12:34:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-announces-closing-of-transaction-with-nexgel\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-announces-closing-of-transaction-with-nexgel\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-announces-closing-of-transaction-with-nexgel\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MzczMSM3NTQ2NjcyIzIyMDUwMDk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MzczMSM3NTQ2NjcyIzIyMDUwMDk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-announces-closing-of-transaction-with-nexgel\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celularity Announces Closing of Transaction with NexGel\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Celularity Announces Closing of Transaction with NexGel - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-announces-closing-of-transaction-with-nexgel\/","og_locale":"en_US","og_type":"article","og_title":"Celularity Announces Closing of Transaction with NexGel - Market Newsdesk","og_description":"FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) &#8212; Celularity Inc. (Nasdaq: CELU) (\u201cCelularity\u201d), a longevity-focused regenerative and cellular medicine company, today announced the closing of its previously announced transaction with NexGel, Inc. (\u201cNexGel\u201d), pursuant to which NexGel acquired certain commercial and other assets related to Celularity\u2019s biomaterials product portfolio and received an exclusive license to develop and commercialize specified products. The transaction is intended to monetize Celularity\u2019s biomaterials portfolio while enabling it to further concentrate resources on advancing its longevity-focused therapeutic pipeline and scalable manufacturing platform. Under the terms of the transaction, Celularity received aggregate consideration of $13.3 million, consisting of $8.3 million in cash at closing and a $5.0 million convertible promissory note from NexGel. In addition, Celularity &hellip; Continue reading \"Celularity Announces Closing of Transaction with NexGel\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-announces-closing-of-transaction-with-nexgel\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-21T12:34:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MzczMSM3NTQ2NjcyIzIyMDUwMDk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-announces-closing-of-transaction-with-nexgel\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-announces-closing-of-transaction-with-nexgel\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Celularity Announces Closing of Transaction with NexGel","datePublished":"2026-04-21T12:34:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-announces-closing-of-transaction-with-nexgel\/"},"wordCount":511,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-announces-closing-of-transaction-with-nexgel\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MzczMSM3NTQ2NjcyIzIyMDUwMDk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-announces-closing-of-transaction-with-nexgel\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-announces-closing-of-transaction-with-nexgel\/","name":"Celularity Announces Closing of Transaction with NexGel - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-announces-closing-of-transaction-with-nexgel\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-announces-closing-of-transaction-with-nexgel\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MzczMSM3NTQ2NjcyIzIyMDUwMDk=","datePublished":"2026-04-21T12:34:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-announces-closing-of-transaction-with-nexgel\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/celularity-announces-closing-of-transaction-with-nexgel\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-announces-closing-of-transaction-with-nexgel\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MzczMSM3NTQ2NjcyIzIyMDUwMDk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MzczMSM3NTQ2NjcyIzIyMDUwMDk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-announces-closing-of-transaction-with-nexgel\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Celularity Announces Closing of Transaction with NexGel"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/953313","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=953313"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/953313\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=953313"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=953313"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=953313"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}